Skip to main content
Midas Edge

IMMUTEP Ltd

For the period ended Aug 31, 2026. Filed Sep 2, 2026.

View on SEC.gov

About this filing

What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.

Aug 31, 2026 · Filed Sep 2, 2026

Use the contents to explore the available documents and sections.

IMMP$3.34+24.2%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

EX-99.1 · Operating segment information

Operating segment information

30 June 2026 · Immunotherapy$ · Unallocated$ · Consolidated$
Revenue
License revenue14,556,923—14,556,923
Other Income
Research material sales38,607—38,607
Grant income5,338,572—5,338,572
Miscellaneous income———
Net gain on foreign exchange—1,229,8511,229,851
Interest income—3,005,0473,005,047
Total revenue and other income19,934,1024,234,89824,169,000
Result
Segment result(81,592,146)2,287,583(79,304,563)
Loss before income tax expense(81,592,146)2,287,583(79,304,563)
Income tax expense———
Loss after income tax expense(79,304,563)
Total segment assets83,267,229—83,267,229
Total segment liabilities21,734,183—21,734,183
30 June 2025Immunotherapy$Unallocated$Consolidated$
Revenue
License revenue———
Other Income
Research material sales59,709—59,709
Grant income4,974,823—4,974,823
Miscellaneous income—390390
Net change in fair value movement—9,2429,242
Interest income—5,287,2095,287,209
Total revenue and other income5,034,5325,296,84110,331,373
Result
Segment result(65,020,504)3,586,339(61,434,165)
Loss before income tax expense(65,020,504)3,586,339(61,434,165)
Income tax expense———
Loss after income tax expense(61,434,165)
Total segment assets156,983,434—156,983,434
Total segment liabilities13,348,071—13,348,071

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.